Express Scripts to Cover Both New Cholesterol Drugs
October 06 2015 - 6:30PM
Dow Jones News
The first major showdown between two new effective but expensive
cholesterol-lowering drugs resulted in a draw.
Express Scripts Holding Co., the big pharmacy-benefits manager,
said it would include both drugs—Praluent from Regeneron Inc. and
Sanofi SA and Repatha from Amgen Inc., on its national list of
covered medicines.
That means that, among the 25 million people whose prescription
plans are managed by Express Scripts, those who are candidates for
the treatments will be able to choose between the two.
Insurance coverage for the two agents, known as PCSK9
inhibitors, has been an unanswered question since the drugs were
approved this summer. The list price for Praluent is about $14,600
a year while Repatha is priced at $14,000.
Both drugs are approved for patients who can't achieve adequate
cholesterol reduction on the widely used class of drugs called
statins, most versions of which are generic and available to
patients for a few dollars a month.
Using the combination of negotiated discounts and a special
program that requires rigorous documentation that patients are
candidates for the drugs, "we were able to achieve the economics we
need" to include both drugs on the formulary, said Steve Miller,
senior vice president and chief medical officer at Express Scripts.
Dr. Miller declined to disclose terms of the discounts.
In a statement, Sanofi and Regeneron said they "are pleased that
patients in the U.S. now have increased access to Praluent" and
that they are "decided to establishing agreements with insurers to
help achieve that goal."
Amgen termed the decision "an important milestone for patients"
and said it "will continue to engage constructively with other
payers to enable patients to have access to Repatha."
The drugs are injectable medicines that dramatically lower LDL
or bad cholesterol that is a key culprit in heart attacks or
strokes. Large scale studies are under way to determine whether the
LDL reduction achieved with the drugs actually translate into fewer
such events.
Write to Ron Winslow at ron.winslow@wsj.com
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=FR0000120578
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US80105N1054
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
October 06, 2015 18:15 ET (22:15 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024